From the Journals
From the Journals
Decitabine elicits favorable response in high-risk AML/MDS
Single-agent therapy with decitabine elicited favorable responses in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS...
From the Journals
Worse outcomes for double-hit lymphomas after ASCT
Patients with double-hit lymphomas and double-expressor lymphomas have inferior outcomes after undergoing autologous stem cell transplantation,...
From the Journals
Ph-like ALL is highly prevalent in adults
Philadelphia chromosome–like acute lymphoblastic leukemia, which is a high-risk subtype of childhood ALL, accounts for more than 24% of ALL in...
From the Journals
HCT survivors experience high rates of late respiratory and infectious complications
Cancer survivors who underwent hematopoietic cell transplantation (HCT) face a greater risk for hospitalizations and mortality, compared with...
From the Journals
DNA methylation markers prognostic for metastatic breast cancer
A novel panel of DNA methylation markers may aid in predicting survival outcomes in metastatic breast cancer.
From the Journals
ADT not associated with increased risk of dementia in larger study
Treatment with androgen deprivation therapy (ADT) was not associated with an increased risk of dementia in a large, population-based study,...
From the Journals
Targeted therapies predicted to blow out costs for CLL
Economic models indicate the annual cost in the United States of managing chronic lymphocytic leukemia will increase from its current level of $0....
Guidelines
ASTRO guidelines lower age thresholds for APBI
APBI can be considered an alternative to whole breast irradiation in patients as young as 40; ductal carcinoma in situ is added as an indication...
From the Journals
Palbociclib extends PFS in advanced breast cancer
Adding the CDK inhibitor palbociclib to standard endocrine therapy extended progression-free survival in a manufacturer-sponsored phase III trial...
From the Journals
Cabozantinib bests sunitinib against metastatic RCC
Cabozantinib showed significant improvements in progression-free survival and objective response rate over standard-of-care sunitinib in a phase...
From the Journals
Nivolumab’s safety profile further clarified
In patients taking nivolumab for advanced melanoma, most immunologic adverse effects are mild to moderate in intensity and resolve when existing...